Abstract

Endovascular treatment is effective for symptomatic peripheral arterial disease (PAD). Following recent device improvements, favorable long-term outcomes have been achieved in iliac arteries as well as small arteries such as the femoral and popliteal arteries.

This paper outlines the history and recent advances in endovascular treatment of peripheral vascular diseases as well as the characteristics and usage of devices. The history and the advances in endovascular treatment of peripheral vascular disease have been parallel, with the development of devices such as catheters and stents. Accordingly, endovascular treatment is now recommended in guidelines as the first-line for PAD.

Key words: peripheral arterial occlusive disease, angioplasty, stent, intervention

(Interventional Radiology 2020; 5: 120-127)

Introduction

Peripheral arterial occlusive disease (PAD) causes organ ischemia by arterial luminal stenosis typically due to arterio- or atherosclerosis.

Although PAD occurs in all arteries, it is most commonly targeted for peripheral endovascular therapy when it occurs in the lower extremity.

Recent advances in interventional devices have allowed active adoption of endovascular treatment for PAD. However, appropriate techniques and strategies should be identified.

This review describes the evolutionary history of endovascular therapy and current advances in its strategies and devices.

History and basic endovascular techniques

Since the 1920s, angiography by direct exposure or puncture of blood vessels has been experimentally performed [1, 2], and angiography for the cerebral arteries [3], the aorta [4], and the lower limb arteries [2] has been reported. However, after the development of the Seldinger technique [5], a percutaneous intravascular catheterization method presented in 1953, the clinical use of angiography became widespread.

After the announcement of the Seldinger technique, various techniques that used catheters were developed. The Dotter method was the first and the most important in angioplasty. The Dotter method is a bougie technique for dilating the stenosis of vessels [6]. After its introduction, the balloon catheter for angioplasty was developed, and peripheral vascular angioplasty became a common procedure (the first successful iliac balloon angioplasty was performed by Gruntzig in 1974) [7, 8].

Received: May 29, 2020. Accepted: July 7, 2020.
doi: 10.22575/interventionalradiology.2020-0014
Correspondence Author: Ryoichi Tanaka. E-mail: rtanaka@iwate-med.ac.jp
Balloon angioplasty was effective, but it was complicated by elastic recoil or early restenosis, and this was a major problem. In the late 1980s, Palmaz developed the balloon-expandable metallic stent [9, 10]. The use of the Palmaz stent in iliac or renal angioplasty improved primary patency [11]. However, in the femoropopliteal artery, its effectiveness was limited to short segmental stenosis [12], and the nitinol self-expandable metallic stent was developed.

Peripheral arterial (occlusive) disease (PAD)

1) Epidemiology, etiology, and inclusion criteria

The major cause of PAD is atherosclerosis [13]. Atherosclerosis is an expression of severe arteriosclerosis, which includes a lipid-rich necrotic core in the plaque, which is called atheroma. The common major risk factors for atherosclerosis are smoking, hypertension, dyslipidemia, and diabetes [14, 15]. As a result of atherosclerosis, coronary, carotid, and renal artery diseases are often associated with lower extremity artery diseases. Therefore, a multidisciplinary approach is recommended.

For patients with lifestyle-limiting claudication and hemodynamically significant aortoiliac occlusive disease, endovascular revascularization is strongly recommended. For femoropopliteal lesions, endovascular revascularization is also considered as a reasonable option [16]. For critical limb ischemia, endovascular revascularization can be justified for minimizing tissue loss by establishing in-line blood flow to the foot [16].

Recent updates to guidelines recommend the use of statins for improving walking distance, with reference to the possible advantage of using clopidogrel over aspirin; however, antiplatelet therapy is limited to asymptomatic lower extremity artery disease. The guidelines also recommend primary endovascular therapy for "TASC-D" aorto-iliac lesions and as first-line for infrapopliteal lesions [17].

2) Interventions

1) Balloon angioplasty

I. conventional balloon angioplasty

Conventional balloon angioplasty is the most traditional procedure for PAD. Balloon catheters have double lumina; one is connected to the end hole as a guidewire lumen and the other is connected to the balloon lumen (Figure 1). The material of a balloon defines the mechanical performance of a catheter. Typically, non-compliant and semi-compliant balloon catheters exist (Figure 2). Non-compliant balloon catheters have relatively stiffer material than their semi-compliant counterparts; generally, they have higher nominal and rated burst pressures and their working diameters are stable irrespective of the pressure (Figure 2A).

Semi-compliant balloon catheters can be used through smaller diameter sheaths, and they can be controlled with less pressure. If a semi-compliant balloon catheter is used for dilating a hard lesion, an expansion of the balloon may cause intimal injury following over-dilatation of both of its...
edges, which results in the so-called “dog-bone” shape (Figure 2B).

(2) Drug-coated balloon

Balloon dilatation of stenotic lesions is usually accompanied by injury of the arterial intima and media, which may lead to intimal hyperplasia and restenosis. Drug-coated balloons were developed to prevent restenosis; embedded paclitaxel crystalline particles on the balloon surfaces are rapidly absorbed into the deep layers of arterial walls. Paclitaxel terminates the cell cycle during the G2 period [18]. The excessive regrowth of smooth muscle cells is suppressed and restenosis is prevented [19]. However, a recent review showed that drug-coated balloons and drug-eluting stents may increase mortality rates within the remote period [20]. Therefore, careful patient selection is required.

(3) Stents

I. Bare-metal stent

A bare-metal stent is a non-drug-coated traditional metallic stent. Initial metallic stents were balloon-expandable, and they were made of stainless steel (SUS 316L) (Figure 3A) [21, 22]; cobalt-chromium alloys are alternative materials [23, 24]. For self-expandable stents, nitinol (nickel-titanium), a shape-memory alloy, is the major material [25–36]. With these metallic implants, metal allergy [37] is thought to be related to in-stent restenosis or stent thrombosis [38–40].

i. Balloon-expandable metallic stent

The dilatation of balloon-expandable metallic stents relies on the expansion of the balloon catheter. Balloon-expandable metallic stents have excellent radial forces, but they are not self-expanding. When they are compressed, they remain deformed and stenosis occurs. Balloon-expandable metallic stents should be selected in target arteries where no external forces are applied.

ii. Self-expandable stent

Self-expanding metallic stents (Figure 3B) are used to treat deformities of the superficial femoral artery, which include axial shortening and elongation, bending, twisting, and pinching [41–43]. The primary patency of the first-generation self-expanding stents in the superficial femoral
artery was not so good [32, 44-48], but improvements in stent design have yielded better outcomes [49-52].

II. Covered stent

Covered stents are alternative devices for improving the late outcomes of treatment for femoropopliteal lesions. Viabahn (W. L. Gore & Associates, Inc., Tokyo) (Figure 4A) is a self-expanding stent covered by heparin-bonded polytetrafluoroethylene and fluorinated ethylene propylene [53]. Viabahn is used to control arterial bleeding and treat chronic total occlusion or long-segment lesions of the superficial femoral artery.

Recently, Viabahn VBX (W. L. Gore & Associates, Inc., Tokyo), which is a balloon-expandable covered stent (Figure 4B), was approved for treating lesions in the iliac arteries of symptomatic PAD patients.

Because of its heparin-bonded material, Viabahn is contraindicated in heparin-induced thrombocytopenia.

III. Drug-eluting stents

Drug-eluting stents achieved favorable long-term patency [54-57] with the suppression of neointimal progression by paclitaxel. The delay of vascular-wall healing after the implantation of drug-eluting stents has been reported and the prolonged use of dual antiplatelet drugs may be considered [58]. The increase in mortality rates by paclitaxel is the same as that of the drug-coated balloon [20].

(4) Other devices

I. Re-entry catheter

The initial step of the endovascular process is to cross the lesion using a guidewire, and although passing through the true lumen is the principle, subintimal angioplasty [59, 60] is an alternative option. Re-entry devices such as OUTBACK (Cardinal Health Japan G.K., Tokyo) (Figure 5) are used for navigating guidewire tips through subintimal spaces to distal true lumina [61-69].

II. High-frequency mechanical vibration

The Crosser CTO recanalization device (Medicon Co., Ltd., Tokyo) (Figure 6) is another alternative for chronic total occlusion [70, 71]. This system can be used to initiate entry into the fibrous cap of the plaque or calcified plaque. A micro guidewire can be advanced through the crosser system after recanalization of a plaque.

Tip vibration that is activated over wires without polymer-jackets and aimed at atherectomy of calcium plaques after the failure of simple balloon angioplasty may be useful [72]; however, this is not documented in the latest package insert information. Careful use is required to avoid guidewire or vessel injury. The slow flow complication after the debulking of plaque should be noted [73].

Drug therapy

Drug therapies are used to improve the outcomes of endovascular therapy. Antiplatelet drugs and anticoagulants are commonly used concomitantly with drugs such as vasodilators, antihyperlipidemics, and antihypertensives.

Heparin, which is an anticoagulant, is used because various devices are used inside the body during the procedure. There are controversies regarding the postoperative heparin combinations [74]. If antiplatelet therapy is not used before endovascular therapy and an implant such as a stent is placed, the use of heparin may be considered until the effect of the combination antiplatelet drug is fully expressed.

Antiplatelet drugs are also used for endovascular therapy. The characteristics of the effect and the time it takes for the effect to manifest depend on the type of drug.

Cilostazol and clopidogrel are commonly used to control platelet aggregation, vasodilation, and intimal hyperproliferation. They are used to prevent early thrombotic re-occlusion and restenosis due to intimal overgrowth at the edge of the stent. Dual antiplatelet therapy is a standard for endovascular therapy [75-78].

Outcomes

Arteriosclerosis is a systemic disease, and PAD is only a part of it. The prognosis of PAD is affected by cerebrovas-
Figure 5. Re-entry device. The reentry device has a retractable needle near the tip of the catheter and is used to navigate a guidewire into the true lumen distal to the occlusion (A). Since the needle exit direction is determined, adjust the needle so that it exits toward the lumen of the blood vessel by referring to the marker at the distal end of the catheter (B). When the tip of the needle enters the lumen of the blood vessel, a guide wire is inserted into the true lumen of the blood vessel through the needle (C). (Images are used under the permission of Cardinal Health Japan GK)

Figure 6. High frequency mechanical vibration device for crossing chronic total occlusion. With hard plaque, such as calcification, the balloon catheter or stent delivery system may not always be able to cross the lesion. In order to pass through such a hard plaque, high frequency mechanical vibration device is used. The metallic tip of the catheter vibrates and crushes hard plaques (A). Dedicated drive is required to vibrate the catheter tip (B). (Images are used under the permission of Medicon Co., Ltd.)

cular and cardiovascular diseases, and the 5-year survival rate is worse in patients with critical limb ischemia than in those with breast or colon cancers [79]. Endovascular treatment for PAD is aimed at alleviating symptoms or improving function rather than extending life.

The long-term primary patency rates of endovascular treatment in the iliac artery are between 80 and 90%. In addition, the primary patency rates in the femoral and popliteal
arteries have improved to approximately 70% within 3 to 5 years due to improvements in stents [49, 51, 80-82]. Endovascular treatment has also been recognized as a standard treatment for these regions.

**Conclusion**

Endovascular treatment is currently a standard treatment for PAD. Improvements in devices and materials are still ongoing, and there are concerns about the use of paclitaxel; however, endovascular therapy is a promising treatment for PAD.

**Conflict of interest:** The authors declare that they have no conflict of interest.

**References**

1. Berberich J, Hirsch S. Die Röntgenographische Darstellung der Arterien und Venen am Lebenden Menschen. Klinische Wochen-schrift 1923; 2: 2226-228.
2. Brooks B. Intra-arterial injection of sodium iodid: preliminary re-port. Journal of the American Medical Association 1924; 82: 1016-1019.
3. Moniz E. L’encephalographie arterielle, son importance dans la localisation des tumeurs cerebrales. Rev Neurol (Paris) 1927; 2: 72.
4. Dos Santos R, Lamas A, Pereira-Caldas J. Arteriografia da aorta e dos vasos abdominais. Med Contemp 1929; 49: 93.
5. Selldinger SI. Catheter replacement of the needle in percutaneous arteriography; a new technique. Acta radiol 1953; 39: 368-376.
6. Dotter Charles T, Judkins Melvin P. Transluminal Treatment of Arteriosclerotic Obstruction. Circulation 1964; 30: 650-670.
7. Barton M, Grünzig J, Husmann M, Rösch J. Balloon Angioplasty: The Legacy of Andreas Grünzig, M.D. (1939-1985). Cardiovascular Medicine 2014; 1: 15.
8. Grünzig A, Hopff H. Perkutane Rekanalisation chronischer arterieller Verschlüsse mit einem neuen Dilatationskatheter. Dtsch Med Wochenschr 1974; 99: 2502-2505.
9. Palmaz JC, Richter GM, Noldge G, Kauffmann GW, Wenz W. In-traluminal Palmaz stent implantation. The first clinical case report on a balloon-expanded vascular prosthesis. Radiologie 1987; 27: 560-563.
10. Palmaz JC. Balloon-expandable intravascular stent. AJR Am J Roentgenol 1988; 150: 1263-1269.
11. Murphy KD, Encarnacion CE, Le VA, Palmaz JC. Iliac artery stent placement with the Palmaz stent: follow-up study. J Vasc Inter-terv Radiol 1995; 6: 321-329.
12. Bergeron P, Pinot JJ, Poyen V, et al. Long-term results with the Palmaz stent in the superficial femoral artery. J Endovasc Surg 1995; 2: 161-167.
13. Hirsch AT, Haskal ZJ, Hertzler NR, et al. ACC/AHA 2005 Practice Guidelines for the Management of Patients With Peripheral Arte-rial Disease (Lower Extremity, Renal, Mesenteric, and Abdominal Aortic). Circulation 2006; 113: e463-e654.
14. Victor A, Marie-Louise B. Epidemiology and risk factors ESC CardioMed. Oxford, UK: Oxford University Press.
15. Victor A, Marianne B. Lower extremity artery disease ESC Cardi-oMed. Oxford, UK: Oxford University Press.
16. Gerhard-Herman MD, Gornik HL, Barrett C, et al. 2016 AHA/ACC Guideline on the Management of Patients With Lower Extremity Peripheral Artery Disease: Executive Summary: A Report of the American College of Cardiology/American Heart Associa-
tion Task Force on Clinical Practice Guidelines. Circulation 2017; 135: e686-e725.
17. Aboyans V, Ricco JB, Bartelink MEL, et al. 2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS): Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries. Endorsed by: the European Society for Vascular Surgery (ESVS). Eur Heart J 2018; 39: 763-816.
18. Yamasaki K, Asai T, Shimizu M, et al. Inhibition of NFκB activation using cis-element ‘decoy’ of NFκB binding site reduces neointimal formation in porcine balloon-injured coronary artery model. Gene Therapy 2003; 10: 356-364.
19. Zeller T, Baumgartner I, Scheinert D, et al. Drug-Eluting Balloon Versus Standard Balloon Angioplasty for Infrapopliteal Arterial Revascularization in Critical Limb Ischemia: 12-Month Results From the IN.PACT DEEP Randomized Trial. Journal of the American College of Cardiology 2014; 64: 1568-1576.
20. Katsanos K, Spiliopoulos S, Kitrou P, Krokidis M, Kambadis D. Risk of Death Following Application of Paclitaxel-Coated Balloons and Stents in the Femoropopliteal Artery of the Leg: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Journal of the American Heart Association 2018; 7: e011245.
21. Schatz RA, Palmaz JC, Tio FO, Garcia F, Garcia O, Reuter SR. Balloon-expandable intracoronary stents in the adult dog. Circulation 1975; 76: 450-457.
22. Schatz RA, Baim DS, Leon M, et al. Clinical experience with the Palmaz-Schatz coronary stent. Initial results of a multicenter study. Circulation 1991; 83: 148-161.
23. Abdel-Wahab M, Toegl R, Kassner G, et al. Long-Term Clinical Outcome of Thin-Strut Cobalt-Chromium Stents in the Drug-Eluting Stent Era: Results of the COBALT (Comparison of Bare-Metal Stents in All-Comers’ Lesion Treatment) Registry. Journal of Interventional Cardiology 2011; 24: 496-504.
24. Kereiakes DJ, Cox DA, Hermiller JB, et al. Usefulness of a cobalt chromium coronary stent alloy. Am J Cardiol 2003; 92: 463-466.
25. Schonefeld E, Torsello G, Osada N, Herten M, Bisdas T, Donas KP. Long-term outcome of femoropopliteal stenting. Results of a prospective study. J Cardiovasc Surg (Torino) 2013; 54: 617-623.
26. Iida O, Soga Y, Hirano K, et al. Long-term outcomes and risk stratification of patency following nitinol stenting in the femoropopliteal segment: retrospective multicenter analysis. J Endovasc Ther 2011; 18: 753-761.
27. Suzuki K, Iida O, Soga Y, et al. Long-term results of the S.M.A.R. T Control(TM) stent for superficial femoral artery lesions, J-SMART registry. Circ J 2011; 75: 939-944.
28. Pulli R, Dorigo W, Fargion A, et al. Early and long-term compari-
son of endovascular treatment of iliac artery occlusions and steno-
sis. J Vasc Surg 2011; 53: 92-98.
29. Kawamura Y, Ishii H, Aoyama T, et al. Nitinol stenting improves primary patency of the superficial femoral artery after percutaneous transluminal angioplasty in hemodialysis patients: a propensity-matched analysis. J Vasc Surg 2009; 50: 1057-1062.
30. Bosiers M, Torsello G, Gissler HM, et al. Nitinol stent implantation in long superficial femoral artery lesions: 12-month results of the DURABILITY I study. J Endovasc Ther 2009; 16: 261-269.
31. Krankenberg H, Schluter M, Steinkamp HJ, et al. Nitinol stent im-
plantation versus percutaneous transluminal angioplasty in superfi-

Interventional Radiology 2020; 5: 120-127
cical femoral artery lesions up to 10 cm in length: the femoral artery stenting trial (FAST). Circulation 2007; 116: 285-292.

32. Schillinger M, Sabeti S, Loewe C, et al. Balloon angioplasty versus implantation of nitinol stents in the superficial femoral artery. N Engl J Med 2006; 354: 1879-1888.

33. Schlager O, Dick P, Sabeti S, et al. Long-segment SFA stenting—the dark sides: in-stent restenosis, clinical deterioration, and stent fractures. J Endovasc Ther 2005; 12: 676-684.

34. Cho L, Roffi M, Mukherjee D, Bhatt DL, Bajzer C, Yadav JS. Superficial femoral artery occlusion: nitinol stents achieve better flow and reduce the need for medications than balloon angioplasty alone. J Invasive Cardiol 2003; 15: 198-200.

35. Jahnke T, Voshage G, Muller-Hulsbeck S, Grimm J, Heller M, Brossmann J. Endovascular placement of self-expanding nitinol coil stents for the treatment of femoropopliteal obstructive disease. J Vasc Interv Radiol 2002; 13: 257-66.

36. Henry M, Amor M, Beyar R, et al. Clinical experience with a new nitinol self-expanding stent in peripheral arteries. J Endovasc Surg 1996; 3: 369-379.

37. Thyssen JP, Menne T. Metal allergy—a review on exposures, penetration, genetics, prevalence, and clinical implications. Chem Res Toxicol 2010; 23: 309-318.

38. Palmerini T, Biondi-Zoccali G, Della Riva D, et al. Stent thrombosis with drug-eluting stents: is the paradigm shifting? J Am Coll Cardiol 2013; 62: 1915-1921.

39. Allagaoglu C, Turan H, Erden I, et al. Relation of Nickel Allergy with in-Stent Restenosis in Patients Treated with Cobalt Chromium Stents. Ann Dermatol 2012; 24: 426-429.

40. Nakajima Y, Itoh T, Morino Y. Metal allergy to everolimus-eluting cobalt chromium stents confirmed by positive skin testing as a cause of recurrent multivessel in-stent restenosis. Catheter Cardiovasc Interv 2016; 87: E137-E142.

41. Ansari F, Pack LK, Brooks SS, Morrison TM. Design considerations for studies of the biomechanical environment of the femoropopliteal arteries. Journal of Vascular Surgery 2013; 58: 804-813.

42. Alexander N, Martin S, Hugh Z, Erich M, Lewis BS. Assessment of self-expanding nitinol stent deformation after chronic implantation into the femoropopliteal arteries. EuroIntervention 2013; 9: 730-737.

43. Ni Ghriallais R, Bruzzi M. A Computational Analysis of the Deformation of the Femoropopliteal Artery With Stenting. Journal of biomechanical engineering 2014; 136.

44. Sasaki Y, Hwang MW, Shirasawa K, et al. Stenting for superficial femoral artery atherosclerotic occlusion: long-term follow-up results. Heart Vessels 2008; 23: 264-270.

45. Pelton AR, Schroeder V, Mitchell MR, Gong XY, Barney M, Robertson SW. Fatigue and durability of Nitinol stents. J Mech Behav Biomed Mater 2008; 1: 153-164.

46. Nikanorov A, Smouse HB, Osman K, Bialas M, Shrivastava S, Schwartz LB. Fracture of self-expanding nitinol stents stressed in vitro under simulated intravascular conditions. J Vasc Surg 2008; 48: 435-440.

47. Dearing DD, Patel KR, Compoginis JM, Kamel MA, Weaver FA, Katz SG. Primary stenting of the superficial femoral and popliteal artery. J Vasc Surg 2009 ;50: 542-547.

48. Zeller T, Tiefenbacher C, Steinkamp HJ, et al. Nitinol stent implantation in TASC A and B superficial femoral artery lesions: the Femoral Artery Conformmex Trial (FACT). J Endovasc Ther 2008; 15: 390-398.

49. Iida O, Urasawa K, Komura Y, et al. Self-Expanding Nitinol Stent vs Percutaneous Transluminal Angioplasty in the Treatment of Femoropopliteal Lesions: 3-Year Data From the SM-01 Trial. J Endovasc Ther 2019; 26: 158-167.

50. Nakamura M, Jaff MR, Settlage RA, Kichikawa K. Nitinol Self-Expanding Stents for the Treatment of Obstructive Superficial Femoral Artery Disease: Three-Year Results of the RELIABLE Japanese Multicenter Study. Ann Vasc Dis 2018; 11: 324-334.

51. Bunte MC, Cohen DJ, Jaff MR, et al. Long-term clinical and quality of life outcomes after stenting of femoropopliteal artery stenosis: 3-year results from the STROLL study. Catheter Cardiovasc Interv 2018; 92: 106-114.

52. Gray WA, Feiring A, Cioppi M, et al. S.M.A.R.T. self-expanding nitinol stent for the treatment of atherosclerotic lesions in the superficial femoral artery (STROLL): 1-year outcomes. J Vasc Interv Radiol 2015; 26: 21-28.

53. Begovac PC, Thomson RC, Fisher JL, Hughson A, Gallhagen A. Improvements in Gore-TEX vascular graft performance by Carmeda BioActive surface heparin immobilization. Eur J Vasc Endovasc Surg 2003; 25: 432-437.

54. Dake Michael D, Ansel GM, Jaff Michael R, et al. Durable Clinical Effectiveness With Paclitaxel-Eluting Stents in the Femoropopliteal Artery. Circulation 2016; 133: 1472-1483.

55. Dake Michael D, Ansel Gary M, Jaff Michael R, et al. Paclitaxel-Eluting Stents Show Superiority to Balloon Angioplasty and Bare Metal Stents in Femoropopliteal Disease. Circulation: Cardiovascular Interventions 2011; 4: 495-504.

56. Dake MD, Ansel GM, Jaff MR, et al. Sustained Safety and Effectiveness of Paclitaxel-Eluting Stents for Femoropopliteal Lesions: 2-Year Follow-Up From the Zilver PTX Randomized and Single-Arm Clinical Studies. Journal of the American College of Cardiology 2013; 61: 2417-2427.

57. Rastan A, Brechtel K, Krankenberg H, et al. Sirolimus-Eluting Stents for Treatment of Infrapopliteal Arteries Reduce Clinical Event Rate Compared to Bare-Metal Stents: Long-Term Results From a Randomized Trial. Journal of the American College of Cardiology 2012; 60: 587-591.

58. Tsukiyama Y, Shinke T, Ishihara T, et al. Vascular response to paclitaxel-eluting nitinol self-expanding stent in superficial femoral artery lesions: post-implantation angiographic findings from the SHIMEJI trial (Suppression of vascular wall Healing after Implantation of drug Eluting peripheral stent in Japanese patients with the Infra inguinal lesion: serial angiographic observation). The International Journal of Cardiovascular Imaging 2019; 35: 1777-1784.

59. Bolia A, Miles KA, Brennan J, Bell PR. Percutaneous transluminal angioplasty of occlusions of the femoral and popliteal arteries by subintimal dissection. Cardiovasc Intervent Radiol 1990; 13: 357-363.

60. Bolia A, Brennan J, Bell PR. Recanalisation of femoro-popliteal occlusions: improving success rate by subintimal recanalisation. Clin Radiol 1989; 40: 325.

61. Patrone L, Stehno O. Retrograde insertion of the outback reentry device from a tribial artery for complex infrainguinal recanalization. CVIR Endovasc 2019; 2: 47.

62. Kawasaki D, Fukunaga M, Nakata T, Kato M, Ohkubo N. Comparison of the OUTBACK(R) Elite Reentry Catheter and the Bi-Directional Approach after Failed Antegrade Approach for Femoropopliteal Occlusive Disease. J Atheroscler Thromb 2017; 24: 1242-1248.

63. Bausback Y, Botbios S, Flux J, et al. Outback catheter for femoro-popliteal occlusions: immediate and long-term results. J Endovasc Ther 2011; 18: 13-21.

64. Beschomer U, Sixt S, Schwarzwalder U, et al. Recanalization of chronic occlusions of the superficial femoral artery using the Out...
back re-entry catheter: a single centre experience. Catheter Cardiovasc Interv 2009; 74(6): 934-938.
65. Gandini R, Del Giudice C, Merolla S, D’Onofrio A, Pampana E, Simonetti G. Bailout alternative use of re-entry device to achieve a chronically occluded superficial artery recanalization without detectable origin. Cardiovasc Interv Radiol 2015; 38: 503-506.
66. Airoldi F, Faglia E, Losa S, et al. A novel device for true lumen re-entry after subintimal recanalization of superficial femoral arteries: first-in-man experience and technical description. Cardiovasc Intervent Radiol 2011; 34: 166-169.
67. Al-Ameri H, Shin V, Mayeda GS, et al. Peripheral chronic total occlusions treated with subintimal angioplasty and a true lumen re-entry device. J Invasive Cardiol 2009; 21: 468-472.
68. Setacci C, Chisci E, de Donato G, Setacci F, Iacoponi F, Galzerano G. Subintimal angioplasty with the aid of a re-entry device for TASC C and D lesions of the SFA. Eur J Vasc Endovasc Surg 2009; 38: 76-87.
69. Haussegger KA, Georgieva B, Portugaller H, Tauss J, Stark G. The outback catheter: a new device for true lumen re-entry after dissection during recanalization of arterial occlusions. Cardiovasc Intervent Radiol 2004; 27: 26-30.
70. Melzi G, Cosgrave J, Biondi-Zoccai GL, et al. A novel approach to chronic total occlusions: the crosser system. Catheter Cardiovasc Interv 2006; 68: 29-35.
71. Laird J, Joye J, Sachdev N, et al. Recanalization of infrainguinal chronic total occlusions with the crosser system: results of the PATRIOT trial. J Invasive Cardiol 2014; 26: 497-504.
72. Tan M, Usarawa K, Koshida R, et al. Evaluation for the efficacy and safety of the crosser catheter as a CTO crossing device and a flossing device. Cardiovascular Intervention and Therapeutics 2018; 33: 77-83.
73. Kobayashi N, Hirano K, Yamawaki M, et al. Clinical Impact and Predictors of the Slow-Flow Phenomenon after Endovascular Treatment of Infrapopliteal Lesions Using the Crosser Catheter in Patients with Critical Limb Ischemia. Journal of Vascular and Interventional Radiology 2020; 31(1): 141-149.
74. Rabah M, Mason D, Muller DWM, et al. Heparin after percutaneous intervention (HAPI): a prospective multicenter randomized trial of three heparin regimens after successful coronary intervention. Journal of the American College of Cardiology 1999; 34: 461.
75. Tepe G, Banteleon R, Brechtel K, et al. Management of peripheral arterial interventions with mono or dual antiplatelet therapy—the MIRROR study: a randomised and double-blinded clinical trial. European Radiology 2012; 22: 1998-2006.
76. Soden PA, Zettervall SL, Ultez KH, et al. Dual antiplatelet therapy is associated with prolonged survival after lower extremity revascularization. Journal of Vascular Surgery 2016; 64: 1633-1644.
77. Beiswenger AC, Jo A, Harth K, Kumins NH, Shishehbor MH, Kashyap VS. A systematic review of the efficacy of aspirin monotherapy versus other antiplatelet therapy regimens in peripheral arterial disease. Journal of Vascular Surgery 2018; 67(6): 1922-1932.
78. Hess Connie N, Norgren L, Ansel Gary M, et al. A Structured Review of Antithrombotic Therapy in Peripheral Artery Disease With a Focus on Revascularization. Circulation 2017; 135: 2534-2555.
79. Norgren L, Hiatt WR, Dormandy JA, Nehler MR, Harris KA, Fowkes FGR. Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). Journal of Vascular Surgery 2007; 45: 55-567.
80. Bosiers M, Setacci C, De Donato G, et al. ZILVERPASS Study: ZILVER PTX Stent vs Bypass Surgery in Femoropopliteal Lesions. J Endovasc Ther 2020; 27: 287-295.
81. Soga Y, Fujihara M, Iida O, et al. Japanese Patients Treated in the IMPERIAL Randomized Trial Comparing Eluvia and Zilver PTX Stents. Cardiovasc Intervent Radiol 2020; 43: 215-222.
82. Vossen RJ, Vahl AC, Leijdekkers VJ, Montauban van Swijndregt AD, Balm R. Long-Term Clinical Outcomes of Percutaneous Transluminal Angioplasty with Optional Stenting in Patients with Superficial Femoral Artery Disease: A Retrospective, Observational Analysis. Eur J Vasc Endovasc Surg 2018; 56: 690-698.